ERBB2 and breast cancer: In a HER/neu mammary tumor mouse model, CD36 expression is induced by anti-HER2 therapy (lapatinib or trastuzumab) and mammary gland-specific cd36 knockout suppresses tumor growth and extends survival (Feng et al., 2019).